We are live on ! Find out more
RNTX

Rein Therapeutics
RNTX

42 hedge funds and large institutions have $16.5M invested in Rein Therapeutics in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 13 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 7

0.08% less ownership

Funds ownership: 1.85% → 1.78% (-0.08%)

2% less funds holding

Funds holding: 43 → 42 (-1)

13% less capital invested

Capital invested by funds: $18.9M → $16.5M (-$2.39M)

62% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 13

Holders
42
Holders Change
-1
Holders Change %
-2.33%
% of All Funds
0.66%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
7
Increased
5
Reduced
13
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
+$62.7K
2
B
Bailard
California
+$57.9K
3
CG
Colony Group
Massachusetts
+$40.9K
4
Citigroup
Citigroup
New York
+$13.6K
5
VF
Virtu Financial
New York
+$9.66K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$302K
2
Renaissance Technologies
Renaissance Technologies
New York
-$186K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$151K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$38.4K
5
William Blair & Company
William Blair & Company
Illinois
-$27.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
US Bancorp
26
US Bancorp
Minnesota
$13K – – –
VF
27
Virtu Financial
New York
$11K +$9.66K +1,067 New
Mercer Global Advisors
28
Mercer Global Advisors
Colorado
$10K -$905 -100 -9%
LSAG
29
Lake Street Advisors Group
New Hampshire
$10K – – –
Cetera Investment Advisers
30
Cetera Investment Advisers
Illinois
$9K -$380 -42 -5%
KA
31
Kovack Advisors
Florida
$7K +$6.79K +750 New
UBS Group
32
UBS Group
Switzerland
$6K -$5.54K -612 -52%
HighTower Advisors
33
HighTower Advisors
Illinois
$6K – – –
KPW
34
Kore Private Wealth
New York
$6K – – –
LPL Financial
35
LPL Financial
California
$5K – – –
RWP
36
Ridgecrest Wealth Partners
California
$5K – – –
TRCT
37
Tower Research Capital (TRC)
New York
$5K +$4.02K +444 +838%
Bank of America
38
Bank of America
North Carolina
$4K -$54 -6 -2%
JP Morgan Chase
39
JP Morgan Chase
New York
$1K +$498 +55 New
Acadian Asset Management
40
Acadian Asset Management
Massachusetts
– -$38.4K -4,247 -100%
TSS
41
Two Sigma Securities
New York
– -$20K -1,733 Closed
Millennium Management
42
Millennium Management
New York
– -$18K -1,577 Closed
Two Sigma Advisers
43
Two Sigma Advisers
New York
– -$6K -565 Closed
Commonwealth Equity Services
44
Commonwealth Equity Services
Massachusetts
– -$6K -540 Closed
HF
45
HRT Financial
New York
– -$5K -532 Closed
Susquehanna International Group
46
Susquehanna International Group
Pennsylvania
– -$6K -503 Closed
SWM
47
Spire Wealth Management
Virginia
– -$1K -112 Closed
Rockefeller Capital Management
48
Rockefeller Capital Management
New York
– +$453 +50 New
1
2

RNTX Hedge Fund Activity: Q1 2022 in Review

42 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q1 2022, worth a combined $16.5M — down 13% from $18.9M a quarter earlier.

Fund positioning in RNTX was balanced in Q1 2022: 7 funds opened new positions, 7 closed out, 5 added to existing stakes and 13 trimmed.

The largest buyer was Ikarian Capital, adding an estimated $62.7K. The largest seller was Morgan Stanley, cutting an estimated $302K.

  • 42 institutional investors held Rein Therapeutics (RNTX) as of Q1 2022, down from 43 in Q4 2021.
  • Funds reported $16.5M of Rein Therapeutics stock for Q1 2022, down 13% quarter-over-quarter.
  • 7 funds opened new Rein Therapeutics positions in Q1 2022 and 7 closed out, a net change of 0 holders.
  • The largest Rein Therapeutics buyer in Q1 2022 was Ikarian Capital, an estimated $62.7K added.
  • The largest Rein Therapeutics seller in Q1 2022 was Morgan Stanley, an estimated $302K sold.

Based on aggregated 13F filings for Q1 2022.